1-4 of 4
Ido Lubin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Using the Iron Chelator Deferasirox to Overcome Drug Resistance in Mantle Cell Lymphoma

Aladin Samara, Saar Shapira, Ido Lubin, Pia Raanani, Galit Granot
Journal: Blood
Blood (2021) 138 (Supplement 1): 4364.
https://doi.org/10.1182/blood-2021-150443
Published: 2021
Journal Articles

Deferasirox Induces Apoptosis in Mantle Cell Lymphoma in a Mechanism Involving Cyclin-D1, p53 and the Ribonucleotide Reductase

Aladin Samara, BSc, MSc, Saar Shapira, MSc, Ido Lubin, PhD, Smadar Avigad, PhD, Pia Raanani, Galit Granot, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1481.
https://doi.org/10.1182/blood.V130.Suppl_1.1481.1481
Published: 2017
Journal Articles

Selective Death of Leukemia Initiating Cells Induced By Deferasirox

Saar Shapira, MSc, Pia Raanani, MD, Arnon Nagler, Ido Lubin, PhD, Nadir Arber, MD, Galit Granot, PhD
Journal: Blood
Blood (2016) 128 (22): 581.
https://doi.org/10.1182/blood.V128.22.581.581
Published: 2016
Journal Articles

Pathogenesis of Ponatinib Associated Vascular Disease in Chronic Myeloid Leukemia: An in Vitro Study

Ayala Gover-Proaktor, PhD, Oren Pasvolsky, MD, Pia Raanani, MD, Arnon Nagler, MD MSc, Saar Shapira, MSc, Ido Lubin, PhD, Galit Granot, PhD, Avi Leader, MD
Journal: Blood
Blood (2015) 126 (23): 2798.
https://doi.org/10.1182/blood.V126.23.2798.2798
Published: 2015